Skip to content
HowShorted

Sana Biotechnology, Inc. short interest in 2022

In 2022, Sana Biotechnology, Inc.'s disclosed short interest ran from 5.02% of shares outstanding on 14 Jan 2022 to 13.48% on 30 Dec 2022, a change of +8.46 percentage points. The year's high was 13.62% on 15 Sep 2022 and its low 5.02% on 14 Jan 2022, averaging 10.75% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 30.29 days on 14 Oct 2022. Full history: Sana Biotechnology, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Sana Biotechnology, Inc. in 2022

2022 in figures

Start of year
5.02% (14 Jan 2022)
End of year
13.48% (30 Dec 2022)
Change
+8.46 pp
High
13.62% (15 Sep 2022)
Low
5.02% (14 Jan 2022)
Average
10.75%
Highest days to cover
30.29 (14 Oct 2022)
SEC filings marked
8

Every report in 2022

Sana Biotechnology, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20225.02%12.22
31 Jan 20225.95%8.16
15 Feb 20226.87%11.93
28 Feb 20227.14%13.54
15 Mar 20227.22%15.41
31 Mar 20228.67%8.6710-K filed, results (8-K)
14 Apr 20229.36%11.20
29 Apr 20229.50%12.23
13 May 20229.83%10.0510-Q filed, results (8-K)
31 May 20229.99%11.65
15 Jun 202210.04%14.44
30 Jun 202211.16%9.34
15 Jul 202211.79%16.47
29 Jul 202212.73%20.70
15 Aug 202212.97%16.9210-Q filed, results (8-K)
31 Aug 202213.40%19.73
15 Sep 202213.62%22.03
30 Sep 202213.38%20.06
14 Oct 202213.29%30.29
31 Oct 202213.34%27.78
15 Nov 202213.07%20.8210-Q filed, results (8-K)
30 Nov 202212.94%27.95
15 Dec 202213.26%29.11
30 Dec 202213.48%21.86

See also: Sana Biotechnology, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.